Rekvina Laboratories share price
BSE: 526075Pharmaceuticals & BiotechnologySmall Cap
Last close ₹55.34down ₹2.91 (5.00%)
Share price at the BSE close on 23 Oct 2026. Previous close ₹58.25.
- Under BSE's graded surveillance, stage 0, on the list for 22 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹62 Cr4,235th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business.
- Net worth zero or below
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 13 Aug 2026
- −139.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- Net worth zero or below
- Volume, BSEVolume. Shares traded on the last trading day.
- 1,921
Results
Standalone; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 13 Aug
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹0.67 Crdown 7.61%
- Net profitNet profit. Under it, net profit in the quarter before. A change in per cent is not worked out where either period is a loss or nothing.
- −₹0.12 CrQuarter to Mar 2026: −₹0.06 Cr
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- −18.0%
Revenue by year
Peak revenue ₹1.27 Cr, year to Mar 2026
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 9 of the 10 years shown
| ₹ crore | Sep 2024Filed 15 Nov | Dec 2024Filed 20 Jan | Mar 2025Filed 13 Jun | Jun 2025Filed 13 Aug | Sep 2025Filed 14 Nov | Dec 2025Filed 6 Feb | Mar 2026Filed 21 May | Jun 2026Filed 13 Aug |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.20 | 0.35 | 0.72 | 0.67 |
| Net profit | −0.07 | −0.02 | −0.04 | −0.04 | −0.03 | −0.12 | −0.06 | −0.12 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | – | – | – | – | −17.8% | −35.9% | −8.4% | −18.0% |
Standalone. The last eight quarters. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, OPERATING SEGMENT, which carries all its revenue.
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Rekvina Laboratories in market cap.
Rekvina Laboratories is not on the chart: it has no P/E or return on equity today
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Vineet LaboratoriesVINEETLAB | 70 | – | – | – | – | – | – | – | 0.00% |
 Zenith DrugsZENITHDRUG | 68 | 17.2 | 0.9 | – | +28.4% | −44.9% | 5.5% | – | 0.00% |
 Onyx BiotecONYX | 67 | – | 1.2 | – | +12.1% | −104.3% | −0.4% | – | 0.00% |
 PhaarmasiaPHRMASI | 62 | 3.5 | 2.8 | 28.6 | +111.8% | – | 114.5% | 7.1% | 0.00% |
 Vivimed LabsVIVIMEDLAB | 50 | – | – | – | – | – | – | – | 0.00% |
 Biofil Chemicals & PharmaceuticalsBIOFILCHEM | 47 | 97.0 | 2.2 | 59.5 | +9.3% | −82.7% | 2.4% | 2.1% | 0.00% |
 Mangalam Drugs and OrganicsMANGALAM | 45 | – | 0.4 | – | −22.3% | – | −30.3% | −12.9% | 0.00% |
 ANG Lifesciences IndiaANG | 43 | – | 0.8 | – | −15.6% | – | −22.8% | −6.3% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
Sep 2026
23 Sep · Announcement under Regulation 30 (LODR)-Change in Registered Office Address
Rekvina Laboratories share price by year
Each calendar year to 2021.Rekvina Laboratories share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2021 | 4.50 | +7.9% | 4.50 | 3.60 |
| 2020 | 4.17 | −3.0% | 4.45 | 4.02 |
| 2019 | 4.30 | −15.7% | 5.30 | 4.30 |
| 2018 | 5.10 | −7.3% | 5.25 | 5.10 |
| 2017 | 5.50 | −20.6% | 7.00 | 4.27 |
| 2016 | 6.93 | −2.9% | 7.29 | 3.99 |
| 2015 | 7.14 | −51.8% | 15.00 | 6.80 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2021 is from its first session, 1 Mar 2021. 2019 is from its first session, 22 Jan 2019. The close is the year's last trade for 2021 (13 Dec 2021), 2020 (11 Mar 2020), 2018 (26 Nov 2018) and 2017 (30 Nov 2017).
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on BSE.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 23 Oct 2026 | 60.99 | 60.99 | 55.34 | 55.34 | 56.38 | 1,921 |
| 22 Oct 2026 | 58.14 | 58.25 | 58.14 | 58.25 | 58.21 | 1,326 |
| 21 Oct 2026 | 60.40 | 62.50 | 60.30 | 61.20 | 61.06 | 6,491 |
| 19 Oct 2026 | 61.50 | 62.10 | 60.20 | 62.10 | 60.37 | 8,045 |
| 16 Oct 2026 | 59.50 | 61.50 | 56.90 | 61.49 | 58.45 | 9,115 |
| 15 Oct 2026 | 62.28 | 65.07 | 58.89 | 59.89 | 62.60 | 8,880 |
| 14 Oct 2026 | 61.98 | 61.98 | 57.00 | 61.98 | 61.42 | 11,295 |
| 13 Oct 2026 | 59.03 | 59.03 | 59.03 | 59.03 | 59.03 | 1,954 |
| 12 Oct 2026 | 56.22 | 56.22 | 56.22 | 56.22 | 56.22 | 1,235 |
| 9 Oct 2026 | 53.55 | 53.55 | 53.55 | 53.55 | 53.55 | 1,132 |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 13 Jan 2026 | Price move | – | Between two trading sessions the price moved by a fifth or more. No corporate action is on record. Not adjusted for. |
| 30 Apr 2014 | Split | 0.5000 | Each share became 2. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout. Any other event is noted and not adjusted for.
Company details
- Legal name
- Rekvina Laboratories Ltd
- BSE code
- 526075
- ISIN
- INE092O01028
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Nov 1993
- Face value
- ₹5
- CIN
- L24231GJ1988PLC011458
- Corporate identity number, the registrar of companies' code for it